Eltrombopag-13C4
Based on 1 publication(s) in Google Scholar
Eltrombopag-13C4 (SB-497115-13C4) is 13C-labeled Eltrombopag. Eltrombopag is an orally active thrombopoietin-receptor non-peptide agonist with platelet-stimulating activity for the study of chronic immune thrombocytopenia. Eltrombopag also has strong inhibitory effects on multidrug-resistant Staphylococcus aureus (Staphylococcus aureus) and can induce apoptosis (apoptosis) in liver cancer cells.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté: 97.89%
- CAS No.: 1217230-31-3
- Formule: C2113C4H22N4O4
- Masse moléculaire:446.44
-
Stockage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
-
Solvant et solubilité
- Pureté et documentation
- Références
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) Eltrombopag-13C4
More
Activité biologique
Thrombopoietin Receptor, Staphylococcus aureus, Apoptosis[1][3][5]
1. This compound can be used as a tracer
2. This compound can be used as an internal standard for quantitative analysis by NMR, GC-MS, or LC-MS.
Chemical Information
-
CAS No. 1217230-31-3
-
Unlabeled Cas 496775-61-2
-
Appearance Solid
-
Masse moléculaire 446.44
-
Formule C2113C4H22N4O4
-
Color Light yellow to orange
-
SMILES
O=[13C](/[13C]1=N/NC(C=CC=C2C3=CC(C(O)=O)=CC=C3)=C2O)N(C(C=C4)=CC(C)=C4C)N=[13C]1[13CH3]
-
Synonyms
SB-497115-13C4
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Publications (1)
-
Journal Impact Factor
-
Most Recent
-
J Pharm Biomed Anal
Simultaneous analysis of avatrombopag, eltrombopag, and hetrombopag in human plasma by UPLC-MS/MS for therapeutic drug monitoring. [Abstract]2023 Oct 25:235:115683. PMID: 37647792
Solvant et solubilité
DMSO : ≥ 20 mg/mL (44.80 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
DMF : ≥ 1 mg/mL (2.24 mM)
Ethanol : ≥ 0.1 mg/mL (0.22 mM)
* "≥" means soluble, but saturation unknown.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Pureté et documentation
-
Fiche technique (274 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Instruction de manipulation (2659 KB)
Références
[1]. Erickson-Miller CL, et al. Preclinical activity of eltrombopag (SB-497115), an oral, nonpeptide thrombopoietin receptor agonist. Stem Cells. 2009 Feb;27(2):424-30. [Content Brief]
[2]. Erickson-Miller CL, et al. Discovery and characterization of a selective, nonpeptidyl thrombopoietin receptor agonist. Exp Hematol. 2005 Jan;33(1):85-93. [Content Brief]
[3]. Lee H, et al. Repurposing Eltrombopag for Multidrug Resistant Staphylococcus aureus Infections. Antibiotics (Basel). 2021 Nov 9;10(11):1372. [Content Brief]
[4]. Juan Zhu, et al. Identification of Eltrombopag as a Repurposing Drug Against Staphylococcus epidermidis and its Biofilms. Curr Microbiol. 2021 Feb 21. [Content Brief]
[5]. Kurokawa T, et al. The Eltrombopag antitumor effect on hepatocellular carcinoma. Int J Oncol. 2015 Nov;47(5):1696-702. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMF / DMSO | 1 mM | 2.2399 mL | 11.1997 mL | 22.3994 mL | 55.9986 mL |
| DMSO | 5 mM | 0.4480 mL | 2.2399 mL | 4.4799 mL | 11.1997 mL |
| 10 mM | 0.2240 mL | 1.1200 mL | 2.2399 mL | 5.5999 mL | |
| 15 mM | 0.1493 mL | 0.7466 mL | 1.4933 mL | 3.7332 mL | |
| 20 mM | 0.1120 mL | 0.5600 mL | 1.1200 mL | 2.7999 mL | |
| 25 mM | 0.0896 mL | 0.4480 mL | 0.8960 mL | 2.2399 mL | |
| 30 mM | 0.0747 mL | 0.3733 mL | 0.7466 mL | 1.8666 mL | |
| 40 mM | 0.0560 mL | 0.2800 mL | 0.5600 mL | 1.4000 mL |
Eltrombopag-13C4 Related Classifications
HY-15306S Related Classifications
Powered by Bioz